HDAC9 and acute myeloid leukemia: Hypomethylating agents, ATRA and HDAC inhibitors modify NKG2D ligand expression in AML especially relevant to NKG2D CAR therapy but also antigen negative innate reactivity, while the CDK inhibitor dinaciclib enhances NK cell recognition of AML blasts predominantly by reducing blast cell HLA-E expression [186,187,188,189].